Transarterial Chemoembolization (TACE) Market Research Report - Forecast till 2032

Transarterial Chemoembolization (TACE) Market Research Report Information By Procedure Type (Conventional TACE and DEB-TACE), By Indication (Unresectable HCC and Early-Stage HCC), By Product Type (Chemotherapeutic Agents, Radiotherapeutic Agents, Drug-eluting Particles, and Others), By End User (Hospitals & Clinics, Cancer Research Centers, and Others), and By Region (North America, Europe, Asia-Pacific, and Rest Of The World) โ€“ Market Forecast Till 2032.

ID: MRFR/HC/7092-HCR | 125 Pages | Author: Rahul Gotadki | February 2024         

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porterโ€™s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE

6.1. Overview

6.2. Conventional TACE

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

6.3. DEB-TACE

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

7. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION

7.1. Overview

7.2. Unresectable HCC

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

7.3. Early-Stage HCC

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

8. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE

8.1. Overview

8.2. Chemotherapeutic Agents

8.2.1. Doxorubicin

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

8.2.2. Cisplatin

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

8.2.3. Mitomycin

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

8.2.4. Others

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

8.3. Radiotherapeutic Agents

8.3.1. Yttrium-90 microspheres

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

8.3.2. Iodine-131 lipiodol

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

8.3.3. Rhenium-188 lipiodol

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

8.3.4. Phosphorus-32 Glass Microspheres

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

8.3.5. Holmium-166 Chitosan Complex

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

8.3.6. Others

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

8.4. Drug-eluting Particles

8.4.1. Polyvinyl Alcohol Microspheres

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

8.4.2. Polymer Microspheres

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

8.5. Others

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

9. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER

9.1. Overview

9.2. Hospitals & Clinics

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

9.3. Cancer Research Centers

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

9.4. Others

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

10. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY REGION

10.1. Overview

10.2. Americas

10.2.1. North America

10.2.1.1. US

10.2.1.2. Canada

10.2.2. Latin America

10.3. Europe

10.3.1. Western Europe

10.3.1.1. Germany

10.3.1.2. France

10.3.1.3. Italy

10.3.1.4. Spain

10.3.1.5. UK

10.3.1.6. Rest of Western Europe

10.3.2. Eastern Europe

10.4. Asia-Pacific

10.4.1. Japan

10.4.2. China

10.4.3. India

10.4.4. Australia

10.4.5. South Korea

10.4.6. Rest of Asia-Pacific

10.5. Middle East & Africa

10.5.1. Middle East

10.5.2. Africa

11. COMPANY LANDSCAPE

11.1.1. Overview

11.1.2. Competitive Analysis

12. COMPANY PROFILES

12.1. Advaxis Inc.

12.1.1. Company Overview

12.1.2. Product Type Overview

12.1.3. Financial Overview

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. Baxter

12.2.1. Company Overview

12.2.2. Product Type Overview

12.2.3. Financial Overview

12.2.4. Key Developments

12.2.5. SWOT Analysis

12.2.6. Key Strategies

12.3. Bellicum Pharmaceuticals, Inc.

12.3.1. Company Overview

12.3.2. Product Type Overview

12.3.3. Financial Overview

12.3.4. Key Developments

12.3.5. SWOT Analysis

12.3.6. Key Strategies

12.4. Boston Scientific Corporation

12.4.1. Company Overview

12.4.2. Product Type Overview

12.4.3. Financial Overview

12.4.4. Key Developments

12.4.5. SWOT Analysis

12.4.6. Key Strategies

12.5. Cook

12.5.1. Company Overview

12.5.2. Product Type Overview

12.5.3. Financial Overview

12.5.4. Key Developments

12.5.5. SWOT Analysis

12.5.6. Key Strategies

12.6. Hikma Pharmaceuticals PLC

12.6.1. Company Overview

12.6.2. Product Type Overview

12.6.3. Financial Overview

12.6.4. Key Developments

12.6.5. SWOT Analysis

12.6.6. Key Strategies

12.7. Isofol Medical AB

12.7.1. Company Overview

12.7.2. Product Type Overview

12.7.3. Financial Overview

12.7.4. Key Developments

12.7.5. SWOT Analysis

12.7.6. Key Strategies

12.8. Nippon Kayaku Co., Ltd.

12.8.1. Company Overview

12.8.2. Product Type Overview

12.8.3. Financial Overview

12.8.4. Key Developments

12.8.5. SWOT Analysis

12.8.6. Key Strategies

12.9. Novartis

12.9.1. Company Overview

12.9.2. Product Type Overview

12.9.3. Financial Overview

12.9.4. Key Developments

12.9.5. SWOT Analysis

12.9.6. Key Strategies

12.10. Pfizer

12.10.1. Company Overview

12.10.2. Product Type Overview

12.10.3. Financial Overview

12.10.4. Key Developments

12.10.5. SWOT Analysis

12.10.6. Key Strategies

12.11. Sirtex SIR-Spheres Pty Ltd.

12.11.1. Company Overview

12.11.2. Product Type Overview

12.11.3. Financial Overview

12.11.4. Key Developments

12.11.5. SWOT Analysis

12.11.6. Key Strategies

12.12. Spectrum Pharmaceuticals, Inc.

12.12.1. Company Overview

12.12.2. Product Type Overview

12.12.3. Financial Overview

12.12.4. Key Developments

12.12.5. SWOT Analysis

12.12.6. Key Strategies

12.13. Others

13. APPENDIX

13.1. References

13.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SYNOPSIS, 2023-2032

TABLE 2 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET ESTIMATES & FORECAST, 2023-2032 (USD MILLION)

TABLE 3 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2023-2032 (USD MILLION)

TABLE 4 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2023-2032 (USD MILLION)

TABLE 5 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2023-2032 (USD MILLION)

TABLE 6 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2023-2032 (USD MILLION)

TABLE 7 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY REGION, 2023-2032 (USD MILLION)

TABLE 8 NORTH AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2023-2032 (USD MILLION)

TABLE 9 NORTH AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2023-2032 (USD MILLION)

TABLE 10 NORTH AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2023-2032 (USD MILLION)

TABLE 11 NORTH AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2023-2032 (USD MILLION)

TABLE 12 US: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY DRUG CLASS, 2023-2032 (USD MILLION)

TABLE 13 US: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2023-2032 (USD MILLION)

TABLE 14 US: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2023-2032 (USD MILLION)

TABLE 15 US: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2023-2032 (USD MILLION)

TABLE 16 CANADA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2023-2032 (USD MILLION)

TABLE 17 CANADA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2023-2032 (USD MILLION)

TABLE 18 CANADA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2023-2032 (USD MILLION)

TABLE 19 CANADA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2023-2032 (USD MILLION)

TABLE 20 LATIN AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2023-2032 (USD MILLION)

TABLE 21 LATIN AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2023-2032 (USD MILLION)

TABLE 22 LATIN AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2023-2032 (USD MILLION)

TABLE 23 LATIN AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2023-2032 (USD MILLION)

TABLE 24 EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2023-2032 (USD MILLION)

TABLE 25 EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2023-2032 (USD MILLION)

TABLE 26 EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2023-2032 (USD MILLION)

TABLE 27 EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2023-2032 (USD MILLION)

TABLE 28 WESTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2023-2032 (USD MILLION)

TABLE 29 WESTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2023-2032 (USD MILLION)

TABLE 30 WESTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2023-2032 (USD MILLION)

TABLE 31 WESTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2023-2032 (USD MILLION)

TABLE 32 EASTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2023-2032 (USD MILLION)

TABLE 33 EASTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2023-2032 (USD MILLION)

TABLE 34 EASTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2023-2032 (USD MILLION)

TABLE 35 EASTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2023-2032 (USD MILLION)

TABLE 36 ASIA-PACIFIC: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2023-2032 (USD MILLION)

TABLE 37 ASIA-PACIFIC: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2023-2032 (USD MILLION)

TABLE 38 ASIA-PACIFIC: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2023-2032 (USD MILLION)

TABLE 39 ASIA-PACIFIC: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2023-2032 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2023-2032 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2023-2032 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2023-2032 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2023-2032 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET

FIGURE 4 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY PROCEDURE TYPE, 2020 (%)

FIGURE 5 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY INDICATION, 2020 (%)

FIGURE 6 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY PRODUCT TYPE, 2020 (%)

FIGURE 7 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY END USER, 2020 (%)

FIGURE 8 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 AMERICAS: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE BY REGION, 2020 (%)

FIGURE 9 NORTH AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 10 EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY REGION, 2020 (%)

FIGURE 11 WESTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 ASIA-PACIFIC: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 MIDDLE EAST & AFRICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 14 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 15 ADVAXIS INC.: KEY FINANCIALS

FIGURE 16 ADVAXIS INC. SEGMENTAL REVENUE

FIGURE 17 ADVAXIS INC.: REGIONAL REVENUE

FIGURE 18 BAXTER: KEY FINANCIALS

FIGURE 19 BAXTER: SEGMENTAL REVENUE

FIGURE 20 BAXTER: REGIONAL REVENUE

FIGURE 21 BELLICUM PHARMACEUTICALS, INC.: KEY FINANCIALS

FIGURE 22 BELLICUM PHARMACEUTICALS, INC.: SEGMENTAL REVENUE

FIGURE 23 BELLICUM PHARMACEUTICALS, INC.: REGIONAL REVENUE

FIGURE 24 BOSTON SCIENTIFIC CORPORATION: KEY FINANCIALS

FIGURE 25 BOSTON SCIENTIFIC CORPORATION: SEGMENTAL REVENUE

FIGURE 26 BOSTON SCIENTIFIC CORPORATION: REGIONAL REVENUE

FIGURE 27 COOK: KEY FINANCIALS

FIGURE 28 COOK: SEGMENTAL REVENUE

FIGURE 29 COOK: REGIONAL REVENUE

FIGURE 30 HIKMA PHARMACEUTICALS PLC: KEY FINANCIALS

FIGURE 31 HIKMA PHARMACEUTICALS PLC: SEGMENTAL REVENUE

FIGURE 32 HIKMA PHARMACEUTICALS PLC: REGIONAL REVENUE

FIGURE 33 ISOFOL MEDICAL AB: KEY FINANCIALS

FIGURE 34 ISOFOL MEDICAL AB: SEGMENTAL REVENUE

FIGURE 35 ISOFOL MEDICAL AB: REGIONAL REVENUE

FIGURE 36 NIPPON KAYAKU CO., LTD.: KEY FINANCIALS

FIGURE 37 NIPPON KAYAKU CO., LTD.: SEGMENTAL REVENUE

FIGURE 38 NIPPON KAYAKU CO., LTD.: REGIONAL REVENUE

FIGURE 39 NOVARTIS: KEY FINANCIALS

FIGURE 40 NOVARTIS: SEGMENTAL REVENUE

FIGURE 41 NOVARTIS: REGIONAL REVENUE

FIGURE 42 PFIZER: KEY FINANCIALS

FIGURE 43 PFIZER: SEGMENTAL REVENUE

FIGURE 44 PFIZER: REGIONAL REVENUE

FIGURE 45 SIRTEX SIR-SPHERES PTY LTD.: KEY FINANCIALS

FIGURE 46 SIRTEX SIR-SPHERES PTY LTD.: SEGMENTAL REVENUE

FIGURE 47 SIRTEX SIR-SPHERES PTY LTD.: REGIONAL REVENUE

FIGURE 48 SPECTRUM PHARMACEUTICALS, INC.: KEY FINANCIALS

FIGURE 49 SPECTRUM PHARMACEUTICALS, INC.: SEGMENTAL REVENUE

FIGURE 50 SPECTRUM PHARMACEUTICALS, INC.: REGIONAL REVENUE

Transarterial Chemoembolization (TACE) Market Segmentation


Transarterial Chemoembolization (TACE) Procedure type Outlook (USD Billion, 2018-2032)




  • Conventional TACE




  • DEB-TACE




Transarterial Chemoembolization (TACE) Indication Outlook (USD Billion, 2018-2032)




  • Unresectable HCC




  • Early-stage HCC




Transarterial Chemoembolization (TACE) Product type Outlook (USD Billion, 2018-2032)




  • Chemotherapeutic agent




  • Radiotherapeutic agent




  • Drug-eluting particles




  • Others




Transarterial Chemoembolization (TACE) End-user Outlook (USD Billion, 2018-2032)




  • Hospital and clinics




  • Cancer research centres




  • Others




Transarterial Chemoembolization (TACE) Regional Outlook (USD Billion, 2018-2032)




  • North America Outlook (USD Billion, 2018-2032)




    • Transarterial Chemoembolization (TACE) by Procedure type




      • Conventional TACE




      • DEB-TACE






    • Transarterial Chemoembolization (TACE) Indication Outlook (USD Billion, 2018-2032)




      • Unresectable HCC




      • Early-stage HCC






    • Transarterial Chemoembolization (TACE) Product type Outlook (USD Billion, 2018-2032)




      • Chemotherapeutic agent




      • Radiotherapeutic agent




      • Drug-eluting particles




      • Others






    • Transarterial Chemoembolization (TACE) End-user Outlook (USD Billion, 2018-2032)




      • Hospital and clinics




      • Cancer research centres




      • Others






    • US Outlook (USD Billion, 2018-2032)




    • Transarterial Chemoembolization (TACE) by Procedure type




      • Conventional TACE




      • DEB-TACE






    • Transarterial Chemoembolization (TACE) Indication Outlook (USD Billion, 2018-2032)




      • Unresectable HCC




      • Early-stage HCC






    • Transarterial Chemoembolization (TACE) Product type Outlook (USD Billion, 2018-2032)




      • Chemotherapeutic agent




      • Radiotherapeutic agent




      • Drug-eluting particles




      • Others






    • Transarterial Chemoembolization (TACE) End-user Outlook (USD Billion, 2018-2032)




      • Hospital and clinics




      • Cancer research centres




      • Others






    • Canada Outlook (USD Billion, 2018-2032)




    • Transarterial Chemoembolization (TACE) by Procedure type




      • Conventional TACE




      • DEB-TACE






    • Transarterial Chemoembolization (TACE) Indication Outlook (USD Billion, 2018-2032)




      • Unresectable HCC




      • Early-stage HCC






    • Transarterial Chemoembolization (TACE) Product type Outlook (USD Billion, 2018-2032)




      • Chemotherapeutic agent




      • Radiotherapeutic agent




      • Drug-eluting particles




      • Others






    • Transarterial Chemoembolization (TACE) End-user Outlook (USD Billion, 2018-2032)




      • Hospital and clinics




      • Cancer research centres




      • Others








  • Europe Outlook (USD Billion, 2018-2032)




    • Transarterial Chemoembolization (TACE) by Procedure type




      • Conventional TACE




      • DEB-TACE






    • Transarterial Chemoembolization (TACE) Indication Outlook (USD Billion, 2018-2032)




      • Unresectable HCC




      • Early-stage HCC






    • Transarterial Chemoembolization (TACE) Product type Outlook (USD Billion, 2018-2032)




      • Chemotherapeutic agent




      • Radiotherapeutic agent




      • Drug-eluting particles




      • Others






    • Transarterial Chemoembolization (TACE) End-user Outlook (USD Billion, 2018-2032)




      • Hospital and clinics




      • Cancer research centres




      • Others






    • Germany Outlook (USD Billion, 2018-2032)




    • Transarterial Chemoembolization (TACE) by Procedure type




      • Conventional TACE




      • DEB-TACE






    • Transarterial Chemoembolization (TACE) Indication Outlook (USD Billion, 2018-2032)




      • Unresectable HCC




      • Early-stage HCC






    • Transarterial Chemoembolization (TACE) Product type Outlook (USD Billion, 2018-2032)




      • Chemotherapeutic agent




      • Radiotherapeutic agent




      • Drug-eluting particles




      • Others






    • Transarterial Chemoembolization (TACE) End-user Outlook (USD Billion, 2018-2032)




      • Hospital and clinics




      • Cancer research centres




      • Others






    • France Outlook (USD Billion, 2018-2032)




    • Transarterial Chemoembolization (TACE) by Procedure type




      • Conventional TACE




      • DEB-TACE






    • Transarterial Chemoembolization (TACE) Indication Outlook (USD Billion, 2018-2032)




      • Unresectable HCC




      • Early-stage HCC






    • Transarterial Chemoembolization (TACE) Product type Outlook (USD Billion, 2018-2032)




      • Chemotherapeutic agent




      • Radiotherapeutic agent




      • Drug-eluting particles




      • Others






    • Transarterial Chemoembolization (TACE) End-user Outlook (USD Billion, 2018-2032)




      • Hospital and clinics




      • Cancer research centres




      • Others






    • UK Outlook (USD Billion, 2018-2032)




    • Transarterial Chemoembolization (TACE) by Procedure type




      • Conventional TACE




      • DEB-TACE






    • Transarterial Chemoembolization (TACE) Indication Outlook (USD Billion, 2018-2032)




      • Unresectable HCC




      • Early-stage HCC






    • Transarterial Chemoembolization (TACE) Product type Outlook (USD Billion, 2018-2032)




      • Chemotherapeutic agent




      • Radiotherapeutic agent




      • Drug-eluting particles




      • Others






    • Transarterial Chemoembolization (TACE) End-user Outlook (USD Billion, 2018-2032)




      • Hospital and clinics




      • Cancer research centres




      • Others






    • Italy Outlook (USD Billion, 2018-2032)




    • Transarterial Chemoembolization (TACE) by Procedure type




      • Conventional TACE




      • DEB-TACE






    • Transarterial Chemoembolization (TACE) Indication Outlook (USD Billion, 2018-2032)




      • Unresectable HCC




      • Early-stage HCC






    • Transarterial Chemoembolization (TACE) Product type Outlook (USD Billion, 2018-2032)




      • Chemotherapeutic agent




      • Radiotherapeutic agent




      • Drug-eluting particles




      • Others






    • Transarterial Chemoembolization (TACE) End-user Outlook (USD Billion, 2018-2032)




      • Hospital and clinics




      • Cancer research centres




      • Others






    • Spain Outlook (USD Billion, 2018-2032)




    • Transarterial Chemoembolization (TACE) by Procedure type




      • Conventional TACE




      • DEB-TACE






    • Transarterial Chemoembolization (TACE) Indication Outlook (USD Billion, 2018-2032)




      • Unresectable HCC




      • Early-stage HCC






    • Transarterial Chemoembolization (TACE) Product type Outlook (USD Billion, 2018-2032)




      • Chemotherapeutic agent




      • Radiotherapeutic agent




      • Drug-eluting particles




      • Others






    • Transarterial Chemoembolization (TACE) End-user Outlook (USD Billion, 2018-2032)




      • Hospital and clinics




      • Cancer research centres




      • Others






    • Rest Of Europe Outlook (USD Billion, 2018-2032)




    • Transarterial Chemoembolization (TACE) by Procedure type




      • Conventional TACE




      • DEB-TACE






    • Transarterial Chemoembolization (TACE) Indication Outlook (USD Billion, 2018-2032)




      • Unresectable HCC




      • Early-stage HCC






    • Transarterial Chemoembolization (TACE) Product type Outlook (USD Billion, 2018-2032)




      • Chemotherapeutic agent




      • Radiotherapeutic agent




      • Drug-eluting particles




      • Others






    • Transarterial Chemoembolization (TACE) End-user Outlook (USD Billion, 2018-2032)




      • Hospital and clinics




      • Cancer research centres




      • Others








  • Asia-Pacific Outlook (USD Billion, 2018-2032)




    • Transarterial Chemoembolization (TACE) by Procedure type




      • Conventional TACE




      • DEB-TACE






    • Transarterial Chemoembolization (TACE) Indication Outlook (USD Billion, 2018-2032)




      • Unresectable HCC




      • Early-stage HCC






    • Transarterial Chemoembolization (TACE) Product type Outlook (USD Billion, 2018-2032)




      • Chemotherapeutic agent




      • Radiotherapeutic agent




      • Drug-eluting particles




      • Others






    • Transarterial Chemoembolization (TACE) End-user Outlook (USD Billion, 2018-2032)




      • Hospital and clinics




      • Cancer research centres




      • Others






    • China Outlook (USD Billion, 2018-2032)




    • Transarterial Chemoembolization (TACE) by Procedure type




      • Conventional TACE




      • DEB-TACE






    • Transarterial Chemoembolization (TACE) Indication Outlook (USD Billion, 2018-2032)




      • Unresectable HCC




      • Early-stage HCC






    • Transarterial Chemoembolization (TACE) Product type Outlook (USD Billion, 2018-2032)




      • Chemotherapeutic agent




      • Radiotherapeutic agent




      • Drug-eluting particles




      • Others






    • Transarterial Chemoembolization (TACE) End-user Outlook (USD Billion, 2018-2032)




      • Hospital and clinics




      • Cancer research centres




      • Others






    • Japan Outlook (USD Billion, 2018-2032)




    • Transarterial Chemoembolization (TACE) by Procedure type




      • Conventional TACE




      • DEB-TACE






    • Transarterial Chemoembolization (TACE) Indication Outlook (USD Billion, 2018-2032)




      • Unresectable HCC




      • Early-stage HCC






    • Transarterial Chemoembolization (TACE) Product type Outlook (USD Billion, 2018-2032)




      • Chemotherapeutic agent




      • Radiotherapeutic agent




      • Drug-eluting particles




      • Others






    • Transarterial Chemoembolization (TACE) End-user Outlook (USD Billion, 2018-2032)




      • Hospital and clinics




      • Cancer research centres




      • Others






    • India Outlook (USD Billion, 2018-2032)




    • Transarterial Chemoembolization (TACE) by Procedure type




      • Conventional TACE




      • DEB-TACE






    • Transarterial Chemoembolization (TACE) Indication Outlook (USD Billion, 2018-2032)




      • Unresectable HCC




      • Early-stage HCC






    • Transarterial Chemoembolization (TACE) Product type Outlook (USD Billion, 2018-2032)




      • Chemotherapeutic agent




      • Radiotherapeutic agent




      • Drug-eluting particles




      • Others






    • Transarterial Chemoembolization (TACE) End-user Outlook (USD Billion, 2018-2032)




      • Hospital and clinics




      • Cancer research centres




      • Others






    • Australia Outlook (USD Billion, 2018-2032)




    • Transarterial Chemoembolization (TACE) by Procedure type




      • Conventional TACE




      • DEB-TACE






    • Transarterial Chemoembolization (TACE) Indication Outlook (USD Billion, 2018-2032)




      • Unresectable HCC




      • Early-stage HCC






    • Transarterial Chemoembolization (TACE) Product type Outlook (USD Billion, 2018-2032)




      • Chemotherapeutic agent




      • Radiotherapeutic agent




      • Drug-eluting particles




      • Others






    • Transarterial Chemoembolization (TACE) End-user Outlook (USD Billion, 2018-2032)




      • Hospital and clinics




      • Cancer research centres




      • Others






    • Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)




    • Transarterial Chemoembolization (TACE) by Procedure type




      • Conventional TACE




      • DEB-TACE






    • Transarterial Chemoembolization (TACE) Indication Outlook (USD Billion, 2018-2032)




      • Unresectable HCC




      • Early-stage HCC






    • Transarterial Chemoembolization (TACE) Product type Outlook (USD Billion, 2018-2032)




      • Chemotherapeutic agent




      • Radiotherapeutic agent




      • Drug-eluting particles




      • Others






    • Transarterial Chemoembolization (TACE) End-user Outlook (USD Billion, 2018-2032)




      • Hospital and clinics




      • Cancer research centres




      • Others








  • Rest of the World Outlook (USD Billion, 2018-2032)




    • Transarterial Chemoembolization (TACE) by Procedure type




      • Conventional TACE




      • DEB-TACE






    • Transarterial Chemoembolization (TACE) Indication Outlook (USD Billion, 2018-2032)




      • Unresectable HCC




      • Early-stage HCC






    • Transarterial Chemoembolization (TACE) Product type Outlook (USD Billion, 2018-2032)




      • Chemotherapeutic agent




      • Radiotherapeutic agent




      • Drug-eluting particles




      • Others






    • Transarterial Chemoembolization (TACE) End-user Outlook (USD Billion, 2018-2032)




      • Hospital and clinics




      • Cancer research centres




      • Others






    • Middle East Outlook (USD Billion, 2018-2032)




    • Transarterial Chemoembolization (TACE) by Procedure type




      • Conventional TACE




      • DEB-TACE






    • Transarterial Chemoembolization (TACE) Indication Outlook (USD Billion, 2018-2032)




      • Unresectable HCC




      • Early-stage HCC






    • Transarterial Chemoembolization (TACE) Product type Outlook (USD Billion, 2018-2032)




      • Chemotherapeutic agent




      • Radiotherapeutic agent




      • Drug-eluting particles




      • Others






    • Transarterial Chemoembolization (TACE) End-user Outlook (USD Billion, 2018-2032)




      • Hospital and clinics




      • Cancer research centres




      • Others






    • Africa Outlook (USD Billion, 2018-2032)




    • Transarterial Chemoembolization (TACE) by Procedure type




      • Conventional TACE




      • DEB-TACE






    • Transarterial Chemoembolization (TACE) Indication Outlook (USD Billion, 2018-2032)




      • Unresectable HCC




      • Early-stage HCC






    • Transarterial Chemoembolization (TACE) Product type Outlook (USD Billion, 2018-2032)




      • Chemotherapeutic agent




      • Radiotherapeutic agent




      • Drug-eluting particles




      • Others






    • Transarterial Chemoembolization (TACE) End-user Outlook (USD Billion, 2018-2032)




      • Hospital and clinics




      • Cancer research centres




      • Others






    • Latin America Outlook (USD Billion, 2018-2032)




    • Transarterial Chemoembolization (TACE) by Procedure type




      • Conventional TACE




      • DEB-TACE






    • Transarterial Chemoembolization (TACE) Indication Outlook (USD Billion, 2018-2032)




      • Unresectable HCC




      • Early-stage HCC






    • Transarterial Chemoembolization (TACE) Product type Outlook (USD Billion, 2018-2032)




      • Chemotherapeutic agent




      • Radiotherapeutic agent




      • Drug-eluting particles




      • Others






    • Transarterial Chemoembolization (TACE) End-user Outlook (USD Billion, 2018-2032)




      • Hospital and clinics




      • Cancer research centers




      • Others







Leading companies partner with us for data-driven Insights.
Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid